Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Klemm
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Klemm

Peter Klemm

CEO, View Point Medical

CrunchbaseLinkedIn

Peter Klemm's Career

View Point Medical
View Point Medical

Carlsbad, CA, US

CEO· C-Suite · Management
Applied Proteomics
Applied Proteomics

San Diego, CA, US

CEO· C-Suite · Management
Predictive Biosciences
Predictive Biosciences

Lexington, KY, US

CEO· C-Suite · Management
Pathwork Diagnostics
Pathwork Diagnostics

Redwood City, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Klemm's Career

View Point Medical
View Point Medical
Series A$30M302016Carlsbad, CA, US
CEO· C-Suite · Management

Leadership at View Point Medical

Jeffrey PortJeffrey PortCo-Founder
William BlairWilliam BlairCo-Founder
Applied Proteomics
Applied Proteomics
Series C$54.5M322006San Diego, CA, US
CEO· C-Suite · Management

Leadership at Applied Proteomics

Lim Kok ThayLim Kok ThayBoard Member
Daniel HillisDaniel HillisFounder
Jim BlairJim BlairBoard Member
Danny HillisDanny HillisBoard Member
Dan AbrutynDan AbrutynBoard Member
R Erik HolmlinR Erik HolmlinBoard Member
Predictive Biosciences
Predictive Biosciences
Pre-Seed$68.1M752006Lexington, KY, US
CEO· C-Suite · Management

Leadership at Predictive Biosciences

Bob LangerBob LangerBoard Member
Michael GreeleyMichael GreeleyBoard Member
Dr M James Barrett \"Jim\"Dr M James Barrett \"Jim\"Board Member
MikeMikeBoard Member

Similar to Predictive Biosciences

Pbs-BioPbs-BioMesa, AZ, USCancer Treatment, Pharmaceutical Researchest. 2006Pbs-BioMesa, AZ, US · est. 2006

Arizona-based Predictive Biomarker Sciences develops innovative cancer treatment technologies for pharmaceutical research.

Angel · $338.1k6
Predictive Health Diagnostics CompanyPredictive Health Diagnostics CompanyIrvine, CA, USDiagnostic Testsest. 2017Predictive Health Diagnostics CompanyIrvine, CA, US · est. 2017

Predictive Health Diagnostics: Transforming data into intelligent, science-driven diagnostic tests.

Series A · $17.3M29
Castle BiosciencesCastle BiosciencesFriendswood, TX, USCancer Testsest. 2008Castle BiosciencesFriendswood, TX, US · est. 2008

Castle Biosciences, Inc.: A U.S. biotech firm offering diagnostic and prognostic cancer testing solutions.

Public · $354.3M543
PrevisePreviseBaltimore, MD, USBiomarker Testingest. 2018PreviseBaltimore, MD, US · est. 2018

Previse: Pioneering early cancer detection through affordable, accurate biomarker technology, starting with esophageal cancer.

Seed · $6.3M12
Pathwork Diagnostics
Pathwork Diagnostics
Acquired$63.5M02002Redwood City, CA, US
Board Member· Board

Leadership at Pathwork Diagnostics

Ken HaasKen HaasBoard Member
Richard KlausnerRichard KlausnerFounder
Greg LahannGreg LahannBoard Member
MOHAMMED SHAHZAD AHMED MALIKMOHAMMED SHAHZAD AHMED MALIKBoard Member
Richard BastianiRichard BastianiBoard Member
Jim TananbaumJim TananbaumBoard Member

Similar to Pathwork Diagnostics

NanopathNanopathCambridge, MA, USDiagnostics, Womens Healthest. 2019NanopathCambridge, MA, US · est. 2019

Nanopath: A molecular diagnostics firm revolutionizing testing for women's health in a single visit.

Series A · $10.3M30
OncocyteOncocyteIrvine, CA, USCancer Diagnosticsest. 2009OncocyteIrvine, CA, US · est. 2009

Oncocyte Corporation: A US-based molecular diagnostics firm, optimizing cancer care through accelerated diagnosis and treatment.

Public · $57.2M75
CblpathCblpathOcala, FL, USLaboratory Services, Molecular Diagnosticsest. 2003CblpathOcala, FL, US · est. 2003

CBLPath, Inc.: Leading provider of specialized pathology and molecular diagnostic lab services since 1988.

Seed · $3.2M124
PrecipioPrecipioNew Haven, CT, USCancer Diagnosticsest. 2011PrecipioNew Haven, CT, US · est. 2011

Precipio: A leading cancer diagnostics lab, providing expert advice for optimal patient care.

Public · $3.3M68

Peter Klemm's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Peter Klemm

Heyward ColemanHeyward ColemanCEO · Viewpoint Molecular TargetingBrian McNeillBrian McNeillBoard Member · Children's Hospital of PhiladelphiaJason PesterfieldJason PesterfieldBoard Member · LumedaJay AckermanJay AckermanCo-Founder & CEO · AttaTeam!